JP2005041851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005041851A5 JP2005041851A5 JP2003300563A JP2003300563A JP2005041851A5 JP 2005041851 A5 JP2005041851 A5 JP 2005041851A5 JP 2003300563 A JP2003300563 A JP 2003300563A JP 2003300563 A JP2003300563 A JP 2003300563A JP 2005041851 A5 JP2005041851 A5 JP 2005041851A5
- Authority
- JP
- Japan
- Prior art keywords
- supplement
- absorption
- utilization rate
- ascorbic acid
- increased
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
この測定結果によると、通常、水に溶けやすいため吸収は早いが体外への排出も早いVCについては、被倹者によって増減にばらつきがあるだけでなく時間が経過するにしたがいその血中濃度、増加率ともに低下しているサプリメントB(表3)に対し、本発明に係るサプリメントA(表1)では時間が経過してもいずれの値も増加している。これは、サプリメントBのようにL−アスコルビン酸またはL−アスコルビン酸Naとして吸収するより、サプリメントAのようにL−アスコルビン酸Ca,Mg,K,Naの総合塩にして摂取したほうが吸収の促進を図ることができるだけでなく体内保有量も多くなり、結果的には排出が少なくなって利用率も上がることを示している。
また、VB2についても、サプリメントA(表2)、サプリメントB(表4)ともに前述のVCと同様の傾向を示しているので、サプリメントAの吸収促進および利用率の向上を図ることができることを示している。なお、VB2は通常、黄色の色素が濃く尿とともに排泄されてしまうが、サプリメントAのようにイオン化ミネラル結合型にすると、尿色素も薄く臭いもわずかとなり、排泄も順延されて体内利用率が多くなることにつながる。
この事実から、本発明に係るサプリメントAは、サプリメントBに比較すると、VCやVB2などビタミンの吸収を促進するとともに体内利用率を高めることができ、同量を摂取した場合は利用効率が向上して長時間にわたり効果を得られるが確認された。According to this measurement result, VC is normally absorbed easily because it is easily dissolved in water, but it is not only variably increased and decreased depending on the subject, but also its blood concentration as time passes. In contrast to the supplement B (Table 3), in which the increase rate is both decreasing, in the supplement A (Table 1) according to the present invention, both values are increased over time. This is because absorption of L-ascorbic acid Ca, Mg, K, Na as a supplemental salt, such as supplement A, promotes absorption rather than absorption as L-ascorbic acid or L-ascorbic acid Na, as in supplement B. In addition to being able to achieve this, the amount in the body increases, and as a result, the discharge is reduced and the utilization rate is increased.
Also, regarding VB2, supplement A (Table 2) and supplement B (Table 4) both show the same tendency as VC described above, indicating that absorption of Supplement A can be promoted and the utilization rate can be improved. ing. VB2 usually has a yellow pigment that is excreted with urine, but when supplemented with ionized minerals like supplement A, the urine pigment is thin and has a slight odor, and excretion is postponed, resulting in a high utilization rate in the body. Will lead to
From this fact, the supplement A according to the present invention can promote the absorption of vitamins such as VC and VB2 and increase the in-vivo utilization rate compared with the supplement B, and the utilization efficiency is improved when the same amount is ingested. It was confirmed that the effect can be obtained for a long time.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003300563A JP4569802B2 (en) | 2003-07-23 | 2003-07-23 | Method for producing an ionized mineral-binding supplement mainly composed of vitamins |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003300563A JP4569802B2 (en) | 2003-07-23 | 2003-07-23 | Method for producing an ionized mineral-binding supplement mainly composed of vitamins |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005041851A JP2005041851A (en) | 2005-02-17 |
JP2005041851A5 true JP2005041851A5 (en) | 2006-05-18 |
JP4569802B2 JP4569802B2 (en) | 2010-10-27 |
Family
ID=34269087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003300563A Expired - Lifetime JP4569802B2 (en) | 2003-07-23 | 2003-07-23 | Method for producing an ionized mineral-binding supplement mainly composed of vitamins |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4569802B2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101119991B (en) | 2005-02-18 | 2012-01-25 | 田边三菱制药株式会社 | Salt of proline derivative, solvate thereof, and production method thereof |
JP5028609B2 (en) * | 2006-02-13 | 2012-09-19 | 眞 八藤 | Method for producing iron supplement composition |
JP2008035714A (en) * | 2006-08-01 | 2008-02-21 | Wakasa Seikatsu:Kk | Health food |
JP5069195B2 (en) * | 2008-08-26 | 2012-11-07 | 眞 八藤 | Salt composition solution |
JP5735906B2 (en) * | 2011-12-28 | 2015-06-17 | 八藤 眞 | Alcohol preparation for noodle production |
JP6211905B2 (en) * | 2013-11-22 | 2017-10-11 | 八藤 眞 | Method for producing ionized metal liquid capable of binding to nutritional components |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9105986A (en) * | 1990-02-05 | 1992-11-10 | Univ Texas | TIME-RELEASE FORMULATION OF VITAMINS, MINERALS AND OTHER BENEFICIAL SUPPLEMENTS |
US5292729A (en) * | 1992-08-14 | 1994-03-08 | Albion International, Inc. | II-bond aromatic vitamin chelates |
DK1155620T3 (en) * | 2000-05-18 | 2005-12-05 | Mega Healthcare As Q | Dietary supplement with vitamins, minerals and polyunsaturated fatty acids |
JP2002369663A (en) * | 2001-06-15 | 2002-12-24 | Kenko Hyakunijussai:Kk | Base food for health care and combined health promotion food |
-
2003
- 2003-07-23 JP JP2003300563A patent/JP4569802B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211077T1 (en) | Sodium nitrite-containing pharmaceutical compositions | |
RU2008118101A (en) | MIXTURE OF IRON AND COPPER SALTS, MASKING METAL TASTE | |
EP1209986A1 (en) | Metal-containing compositions, preparations and uses | |
KR20110128329A (en) | Phosphate adsorbent | |
RU2009115791A (en) | MIXTURE OF IRON AND COPPER SALTS, MASKING METAL TASTE | |
WO2004017998A3 (en) | Topical emulsion- gel composition comprising diclofenac sodium | |
JP2005041851A5 (en) | ||
JPWO2010041647A1 (en) | Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition as an active ingredient | |
JP2009514786A5 (en) | ||
JP2003508467A5 (en) | ||
RU2006109966A (en) | YANTASTIM-S DRUG FOR THERAPY AND PREVENTION OF ANIMAL INFECTIOUS DISEASES | |
DS | AMALGAMATION OF AYURVEDIC CONCEPT WITH MODERN MEDICAL PRACTICE TO MANAGE KIDNEY STONE DISEASE (UROLITHIASIS): AN ABBREVIATED REVIEW. | |
US7910137B2 (en) | Metal carnitine chelates | |
JPS58165774A (en) | Drink composition | |
Ulemale et al. | Fluorosis in cattle | |
Lina et al. | The role of alkalizing and neutral potassium salts in urinary bladder carcinogenesis in rats | |
JPS60197624A (en) | Urine-alkalizing food composition | |
TWI312340B (en) | ||
JP3024896B2 (en) | Anemia ameliorating material | |
JP2003321371A (en) | Diuretic | |
ATE259778T1 (en) | NON-HYGROSCOPIC SALTS OF ACTIVE INGREDIENTS HAVING THERAPEUTIC AND/OR NUTRITIONAL PROPERTIES AND ORAL COMPOSITIONS CONTAINING SAME | |
JP2004166690A (en) | Zinc-containing product having antioxidative effect | |
JP5915013B2 (en) | Oral solution | |
JP2001151682A (en) | Substance for activating biofunction | |
Kaniovska et al. | SELENIUM, A TRACE ELEMENT, AND POSSIBILITIES OF ITS APPLICATION IN PATHOLOGY OF INTERNAL ORGANS |